Phase Ia/Ib single-centre, randomised, placebo-controlled, double-blind, dose-escalation study trial of SPI 3608 in healthy volunteers
Phase of Trial: Phase I
Latest Information Update: 07 Aug 2013
Price : $35 *
At a glance
- Drugs SPI 3608 (Primary)
- Indications Musculoskeletal pain
- Focus Adverse reactions
- 07 Aug 2013 Positive top-line results published in a Sucampo Pharmaceuticals media release.
- 07 Aug 2013 Status changed from recruiting to completed, according to a Sucampo Pharmaceuticals media release.
- 14 May 2013 New trial record